|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02367 GIANT BIOGENE
Nominal 
29.600 +1.160 (+4.079%) | 2026/06 - Interim RMB(K¥) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | 1,780,622 | 2,041,202 | 1,647,431 | 931,637 |
| Net Cash from / (used in) Investing Activities | -- | (318,735) | (1,106,121) | (527,282) | (858,737) |
| Net Cash from / (used in) Financing Activities | -- | 917,991 | 582,948 | 51,808 | (5,789,766) |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | 2,379,878 | 1,518,029 | 1,171,957 | (5,716,866) |
| Cash & Cash Equivalents at beginning of period | -- | 4,030,207 | 2,503,999 | 1,330,951 | 7,103,000 |
| Effect of Foreign Exchange Rate Changes | -- | (103,925) | 8,179 | 1,091 | (55,183) |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 6,306,160 | 4,030,207 | 2,503,999 | 1,330,951 |
| Remarks: | Real time quote last updated: 20/08/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 939,714 |
| %Change | -20.504% |
| EPS / (LPS) | RMB 0.890 |
| NBV Per Share (¥) | RMB 8.814 |